New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
09:09 EDTPRANPrana completes recruitment in IMAGINE trial
Prana Biotechnology announced that it has completed recruitment in the IMAGINE trial, a 12 month Phase II trial testing PBT2, the Company's drug in development for Alzheimer's Disease. The double-blind placebo controlled trial has enrolled 41 patients with prodromal or mild Alzheimer's Disease in Melbourne, Australia. One additional patient may be included in the trial, subject to final screening procedures this week. All trial participants are undergoing brain scans to measure PBT2's effect on amyloid deposits in the brain and effects on increasing brain activity.
News For PRAN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
11:47 EDTPRANPrana founder claims breakthrough Alzheimer's approach, FierceBiotech says
The scientific founder of Prana Biotechnology, Massachusetts General Hospital investigator Rudy Tanzi, is asserting that he and his fellow researchers have come upon a new approach to growing brain cells in the lab that promises to "revolutionize" Alzheimer's research, reported FierceBiotech. Tanzi is the co-founding scientist and Chief Scientific Adviser at Prana. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use